Provided is a pharmaceutical composition and use thereof in treating a chronic kidney disease. In the pharmaceutical composition, Astragalus membranaceus is adopted for strengthening body resistance, and Radix et Rhizoma Rhei, Whitmania pigra (W. pigra), and Bombyx batryticatus (B. batryticatus) are adopted for eliminating pathogens, that is, the pharmaceutical composition can improve a kidney function through the combination of strengthening body resistance with eliminating pathogens. The above treatments all can significantly reduce creatinine, urea nitrogen, and urine protein/creatinine ratio indexes in rats with chronic renal failure (CRF), and improve pathological changes such as glomerular mesangial expansion, extracellular matrix deposition of mesangial cells, glomerulosclerosis, and renal interstitial fibrosis (RIF) in rats (a model) with CRF, thereby further improving a therapeutic effect of the TCM composition for CKD.

Disclosed herein are fusion proteins comprising a truncated thrombostasin protein having at least 85% sequence homology to a thrombostasin protein, wherein the thrombostasin protein has a carboxy terminal deletion; and a fusion partner protein that is a non-thrombostasin protein. Further disclosed are vaccine compositions thrombostasin proteins having a comprising a carboxy terminal deletion, and methods for inhibiting a response to a thrombostasin protein in a host in need thereof, comprising the disclosed fusion proteins or vaccine compositions. Further disclosed are methods for the preparation of a fusion protein composition.

Uses are described for hemolymph, contents of hemolymph, fragments or components of the contents found within hemolymph, including hemocyanin, any of which may be derived from crustaceans, as functional agents to treat diseases, provide symptomatic relief, provide a beautifying or relieving effect to the intended organ or site-of-intended-use, or be used as an ingredient in formulations designed to aid in the relief of pathologies or states commonly associated with inflammation and dry skin, including, but not limited to eczema, dermatitis, psoriasis, cystitis, asthma, sinusitis, joint pain, as well as other instances of acute and chronic inflammation, and for relief of general symptoms that may be associated with inflammation and dry skin but not linked directly in the intended use, including, but not limited to, redness, itchiness, irritation, muscle or joint fatigue, swelling, hydrating the skin, and reducing transepidermal water loss (TEWL).

Uses are described for hemolymph, contents of hemolymph, fragments or components of the contents found within hemolymph, including hemocyanin, any of which may be derived from crustaceans, as functional agents to treat diseases, provide symptomatic relief, provide a beautifying or relieving effect to the intended organ or site-of-intended-use, or be used as an ingredient in formulations designed to aid in the relief of pathologies or states commonly associated with inflammation and dry skin, including, but not limited to eczema, dermatitis, psoriasis, cystitis, asthma, sinusitis, joint pain, as well as other instances of acute and chronic inflammation, and for relief of general symptoms that may be associated with inflammation and dry skin but not linked directly in the intended use, including, but not limited to, redness, itchiness, irritation, muscle or joint fatigue, swelling, hydrating the skin, and reducing transepidermal water loss (TEWL).

Uses are described for hemolymph, contents of hemolymph, fragments or components of the contents found within hemolymph, including hemocyanin, any of which may be derived from crustaceans, or recombinantly produced, as functional agents to treat diseases, provide symptomatic relief, provide a beautifying or relieving effect to the intended organ or site-of-intended-use, or be used as an ingredient in formulations designed to help regenerate, repair, or restore the function of the skin barrier, for applications falling within skin barrier restoration, wound healing and anti-aging effects.

An improved method for the manufacture of a medicament, which method includes the use of tissues, larval forms or derivatives of insects that have been fed on food containing pathogens.

An improved method for the manufacture of a medicament, which method includes the use of tissues, larval forms or derivatives of insects that have been fed on food containing pathogens.